HBM Healthcare Investments publishes a net asset value (NAV) per share of CHF 270.92 as of September 30, 2022.

Net Asset Value (NAV) per share on 30 September 2022 was CHF 270.92, 1.7% lower than at the start of 2022/23. By contrast, the MSCI World Healthcare Sector Index fell 7.7% and the Nasdaq Biotechnology Index fell 3.1%.

Based on the reported NAV, HBM Healthcare Investments expects a loss of CHF 34 million in the first half. This result was largely influenced by the public investment in Cathay Biotech. The company’s market capitalization on the Shanghai Stock Exchange has fallen by more than a fifth. A leader in the growing synthetic biology market, Cathay Biotech is debt-free and profitable with continued sales and profit growth. The remaining private and public investments in the portfolio have experienced positive values ​​across the board. This is also due to his four acquisitions of Sierra Oncology, Biohaven, Turning Point Therapeutics and most recently his ChemoCentryx from a portfolio of publicly traded companies.

The numbers shown here are preliminary results based on the current status of the closing process. The final results will be published with the semi-annual report on October 21, 2022.